Articles
Sequence Listings in IPR Proceedings: Patent Owners Must Know
If you are a patent owner in the biotechnology or pharmaceutical space, understanding how sequence listing IPR proceedings work is no longer optional. Inter Partes Review (IPR) has become one of the most powerful tools used to challenge patents, and when your patent covers biological sequences such as DNA, RNA, or amino acid chains, the stakes get even higher. A misstep in how your sequence data is presented, formatted, or disclosed can cost you your patent. This guide is designed to help you understand sequence listing IPR proceedings in a clear, practical, and straightforward way.
What Is an IPR Proceeding and Why Does It Matter?
An Inter Partes Review (IPR) is a trial proceeding conducted by the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO). It allows third parties, usually competitors, to challenge the validity of an issued patent based on prior art, specifically through patents or printed publications.
IPR proceedings have become extremely popular since they were introduced under the America Invents Act (AIA) in 2012. They are faster and cheaper than district court litigation, which makes them an attractive weapon for those who want to invalidate a patent. For biotech and pharmaceutical patent owners, this means your sequence-based patents are exposed to serious scrutiny.
The core issue with sequence listing IPR proceedings is this: biological sequence data must be disclosed in a specific, standardized format. If the sequences in your patent are not properly listed, organized, or formatted, it can affect how prior art is interpreted, how claims are constructed, and whether your patent survives a challenge.
What Is a Sequence Listing and Why Is It So Important?
A sequence listing is a formal, structured document that discloses nucleotide or amino acid sequences claimed in a patent application. The USPTO requires this under specific rules, and since July 2022, the new WIPO Standard ST.26 has replaced the older ST.25 format for all new international and U.S. patent filings.
In the context of sequence listing IPR proceedings, the sequence listing is not just an administrative formality. It becomes central evidence. Here is why it matters so much:
- Claim interpretation depends on it. If your patent claims a specific DNA sequence or protein, the sequence listing defines the exact boundaries of that claim. Any ambiguity can be used against you.
- Prior art comparisons use it. When a petitioner challenges your patent, they compare your sequences against prior art sequences. A poorly formatted or incomplete sequence listing makes this comparison harder to defend.
- Compliance failures can be fatal. If your sequence listing does not comply with USPTO or WIPO standards, it can raise questions about the sufficiency of your disclosure, which could weaken your position in an IPR.
Key Challenges Patent Owners Face in Sequence Listing IPR Proceedings
Understanding the challenges is the first step toward protecting your patent. Here are the most common issues that arise during sequence listing IPR proceedings:
1. Format Non-Compliance The shift from ST.25 to ST.26 has created confusion. Many older patents were filed under ST.25, and when they face IPR challenges, petitioners may argue that the sequence data is not accessible, searchable, or clearly defined under current standards.
2. Sequence Numbering Errors Every sequence in a patent must be assigned a unique SEQ ID NO. Errors in numbering, skipping sequences, or inconsistencies between the specification and the sequence listing can create gaps in your claim coverage.
3. Incomplete or Missing Sequences If a sequence referenced in your claims does not appear in the sequence listing, or if the listing omits partial sequences or fragments that matter to the claims, you could face an enablement or written description challenge during IPR.
4. Inconsistencies Between the Specification and the Listing When the written description of your patent refers to a sequence differently than how it is listed in the formal sequence listing, petitioners use that inconsistency to argue claim ambiguity.
What Patent Owners Must Do to Protect Their Patents?
Proactive preparation is your best defense. Below are the critical steps every patent owner should take when dealing with sequence listing IPR proceedings:
- Audit your sequence listings before any challenge arrives. Review all SEQ ID NOs against your claims and specification to confirm they are complete, accurate, and consistent.
- Ensure ST.26 compliance for any continuation or reissue applications. If you are filing continuations of older ST.25-based patents, work with a qualified sequence listing specialist to convert and verify compliance.
- Document your sequence data chain of custody. Maintain clear records of how and when sequence data was generated, to counter prior art arguments during IPR.
- Work with both patent attorneys and sequence listing experts together. Technical formatting errors often go unnoticed by legal teams. A dedicated sequence listing professional can spot issues that could otherwise become vulnerabilities in an IPR.
- Cross-check sequences in the claims against the listing at every stage. This should happen during prosecution and again during any post-grant review preparation.
The Role of Sequence Listing Experts in IPR Defense
One of the most overlooked aspects of sequence listing IPR proceedings is the value of having a dedicated sequence listing expert on your defense team. Most IPR cases rely heavily on legal strategy, but when biological sequences are at the center of the dispute, technical precision is equally important.
A sequence listing expert can help you identify formatting vulnerabilities before a petitioner does, prepare technically accurate declarations, and ensure that the sequence data presented to the PTAB is clean, compliant, and clearly supports your claims.
At The Sequence Listing, our team works directly with patent owners and legal counsel to prepare, review, and defend sequence listings in IPR proceedings. We understand both the technical requirements of ST.26 and the strategic demands of PTAB litigation.
Final Thoughts
Sequence listing IPR proceedings are complex, technical, and high-stakes. For patent owners in biotech and pharma, the quality and compliance of your sequence listing can determine whether your patent stands or falls under challenge. Do not wait for a petition to land before reviewing your sequence data. Act early, work with the right experts, and make sure your sequence listing is your strongest asset, not your weakest link.
If you have questions about your sequence listing or need help preparing for a potential IPR challenge, reach out to the experts at The Sequence Listing.
We are the leading Patent Sequence Listing Company
At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.
Our Expertise
- Specialized expertise in WIPO ST.25 and ST.26 standards
- Customized solutions for complex biological sequences
- Guaranteed compliance with patent office requirements
- Rapid 24-48 hour turnaround time
- Comprehensive quality assurance process
Trust Your Patent Sequence Listings to the Industry's Leading Experts
Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.
Office
- Suite-427,425 Broadhollow Road Melville | NY-11747